Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data

INTRODUCTION: Pembrolizumab is a programmed death-ligand 1 inhibitor that was initially indicated for monotherapy in patients with advanced lung cancer. The Japanese Lung Cancer Society conducted an observational study on pembrolizumab using confirmative data obtained through postmarketing all-case...

Descripción completa

Detalles Bibliográficos
Autores principales: Terai, Hideki, Soejima, Kenzo, Shimokawa, Asanao, Horinouchi, Hidehito, Shimizu, Junichi, Hase, Tetsunari, Kanemaru, Ryota, Watanabe, Kana, Ninomiya, Kiichiro, Aragane, Naoko, Yanagitani, Noriko, Sakata, Yoshihiko, Seike, Masahiro, Fujimoto, Daichi, Kasajima, Masashi, Kubo, Akihito, Kusumoto, Sojiro, Oyamada, Yoshitaka, Fujiwara, Keiichi, Mori, Masahide, Hashimoto, Midori, Shingyoji, Masato, Kodani, Masahiro, Sakamoto, Jin, Agatsuma, Toshihiko, Kashiwabara, Kosuke, Inomata, Minehiko, Tachihara, Motoko, Tanaka, Kazuhisa, Hayashihara, Kenji, Koyama, Nobuyuki, Matsui, Kaoru, Minato, Koichi, Jingu, Daisuke, Sakashita, Hiroyuki, Hara, Satoshi, Naito, Tomoyuki, Okada, Asuka, Tanahashi, Masayuki, Sato, Yuki, Asano, Koichiro, Takeda, Takayuki, Nakazawa, Kensuke, Harada, Toshiyuki, Shibata, Kazuhiko, Kato, Tatsuo, Miyaoka, Etsuo, Yoshino, Ichiro, Gemma, Akihiko, Mitsudomi, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579417/
https://www.ncbi.nlm.nih.gov/pubmed/36275911
http://dx.doi.org/10.1016/j.jtocrr.2022.100404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579417/
https://www.ncbi.nlm.nih.gov/pubmed/36275911
http://dx.doi.org/10.1016/j.jtocrr.2022.100404

Ejemplares similares